Whats new
Whats new.
Baird - Encouraged by Efti Topline Results in PD-L1 Negative Head and Neck Cancer; Rated Outperform, $7 tgt (Analyst: Joel L. Beatty, MD, CFA)
April 24th 2024
For a copy of this research report please contact your Baird advisor
Whats new
April 24th 2024
For a copy of this research report please contact your Baird advisor